Camrelizumab with carboplatin and nab-paclitaxel shows potential as a first-line treatment for ES-SCLC, with promising survival rates. The study identified biomarkers, including MUC17 alterations and ...
Please provide your email address to receive an email when new articles are posted on . Survival outcomes did not differ for patients with HNSCC who received radiotherapy with carboplatin-paclitaxel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback